Literature DB >> 19259822

Targeting p53 for enhanced radio- and chemo-sensitivity.

Chao Lu1, Wafik S El-Deiry.   

Abstract

p53 acts as a central mediator of the cellular response to stressful stimuli. The growth-suppressive function of p53 is lost with mutation and this occurs commonly in human cancer. In addition to suppressing cancer development and progression, wild-type p53 further confers chemo-sensitivity and radio-sensitivity upon tumor cells. Accumulated evidence over the last two decades that wild-type p53 activity is required for the efficacy of radiation and chemotherapy has led to considerable interest in development of strategies to restore normal p53 function in tumors with defective p53-dependent signaling. A number of promising discoveries, based on the knowledge of structural and functional basis of p53 mutation, p53 degradation by MDM2 and p53 family proteins, provide a foundation for future drug design. Here we review the role of p53 in enhancing the sensitivity from radiation and chemotherapy and discuss current progress on therapies targeting p53.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19259822     DOI: 10.1007/s10495-009-0330-1

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  56 in total

1.  The novel tryptamine derivative JNJ-26854165 induces wild-type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias.

Authors:  Kensuke Kojima; Jared K Burks; Janine Arts; Michael Andreeff
Journal:  Mol Cancer Ther       Date:  2010-08-24       Impact factor: 6.261

2.  Acute lymphoblastic leukemia cells that survive combination chemotherapy in vivo remain sensitive to allogeneic immune effects.

Authors:  Johan Jansson; Yu-Chiao Hsu; Igor I Kuzin; Andrew Campbell; Craig A Mullen
Journal:  Leuk Res       Date:  2010-11-12       Impact factor: 3.156

3.  A mammalian functional-genetic approach to characterizing cancer therapeutics.

Authors:  Hai Jiang; Justin R Pritchard; Richard T Williams; Douglas A Lauffenburger; Michael T Hemann
Journal:  Nat Chem Biol       Date:  2010-12-26       Impact factor: 15.040

4.  p53 modulates acquired resistance to EGFR inhibitors and radiation.

Authors:  Shyhmin Huang; Sergio Benavente; Eric A Armstrong; Chunrong Li; Deric L Wheeler; Paul M Harari
Journal:  Cancer Res       Date:  2011-11-08       Impact factor: 12.701

5.  Glycogen synthase kinase 3β inhibitors protect hippocampal neurons from radiation-induced apoptosis by regulating MDM2-p53 pathway.

Authors:  D K Thotala; D E Hallahan; E M Yazlovitskaya
Journal:  Cell Death Differ       Date:  2011-07-08       Impact factor: 15.828

6.  The transcription factor CREBZF is a novel positive regulator of p53.

Authors:  Irene López-Mateo; M Ángeles Villaronga; Susana Llanos; Borja Belandia
Journal:  Cell Cycle       Date:  2012-09-14       Impact factor: 4.534

Review 7.  Role of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies.

Authors:  Lindsey N Micel; John J Tentler; Peter G Smith; Gail S Eckhardt
Journal:  J Clin Oncol       Date:  2013-01-28       Impact factor: 44.544

Review 8.  MicroRNAs in the ionizing radiation response and in radiotherapy.

Authors:  Chanatip Metheetrairut; Frank J Slack
Journal:  Curr Opin Genet Dev       Date:  2013-02-28       Impact factor: 5.578

9.  Simultaneous analysis of p53 protein expression and cell proliferation in irradiated human lymphocytes by flow cytometry.

Authors:  Rafael de Freitas E Silva; Neyliane Frassinetti Gonçalves Dos Santos; Valéria Rěgo Alves Pereira; Ademir Amaral
Journal:  Dose Response       Date:  2013-08-27       Impact factor: 2.658

10.  p53 suppresses structural chromosome instability after mitotic arrest in human cells.

Authors:  W B Dalton; B Yu; V W Yang
Journal:  Oncogene       Date:  2010-01-11       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.